Aptevo Therapeutics Inc (APVO) Stock Price, Quote & News

Company Profile

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 838 0500

Fax: 206 838 0503

Website: aptevotherapeutics.com

Address:

2401 4th Avenue, Suite 1050, Seattle, United States

DonZulu Sep. 8 at 5:07 PM

$APVO starting a move into january PT 30$ This is hitting bottom

0 · Reply

macstock Sep. 7 at 2:48 AM

$APVO looks like this turd is finally out of suckers to keep it floating

0 · Reply

jerrik Sep. 5 at 3:04 PM

$APVO Not sure which platforms show the press releases so just sharing this video: https://www.redchip.com/media/3243/aptevo-therapeutics-inside-a-top-tier-oncology-pipeline-with-coo-jeff-lamothe

1 · Reply

HFH_Inc Sep. 4 at 3:01 PM

$APVO Wen next Reverse Split?

1 · Reply

Annet_why_net Sep. 4 at 2:54 PM

$APVO 👀

0 · Reply

MrTicker Sep. 4 at 12:51 PM

$APVO Aptevo Expands Anti-Cancer Pipeline With Patents For APVO452, APVO451; Acute Myeloid Leukemia Candidate Mipletamig Shows Strong Clinical Validation BENZINGA 7:50 AM ET 9/4/2025

0 · Reply

The_Gambl3r Sep. 4 at 3:43 AM

$APVO 👀👀

0 · Reply

doodledo77 Aug. 28 at 4:30 PM

$APVO watching... Some just added 56k👀👀

0 · Reply

DaBullRunner Aug. 28 at 11:03 AM

$APVO there it goes PZG loading 🚢📦📦📦📦📦📦📦🚨 WATCH AND LEARN LIKE THIS👇

0 · Reply

doodledo77 Aug. 27 at 8:01 PM

$APVO watching this money maker 👀👀👀😉

1 · Reply

Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules

Aug 13, 2025, 8:05 AM EDT - 26 days ago

Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

Aug 11, 2025, 8:05 AM EDT - 4 weeks ago

Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update

Jun 20, 2025, 11:30 AM EDT - 2 months ago

Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 20, 2025, 8:55 AM EDT - 2 months ago

Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers

Jun 20, 2025, 8:01 AM EDT - 2 months ago

Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

SWBI

Jun 18, 2025, 1:34 PM EDT - 2 months ago

Aptevo More Than Doubles After Favorable Results in Leukemia Study

Jun 18, 2025, 11:37 AM EDT - 2 months ago

Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer

Jun 18, 2025, 10:52 AM EDT - 2 months ago

Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules

Jun 18, 2025, 8:01 AM EDT - 2 months ago

Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML

Jun 13, 2025, 8:05 AM EDT - 3 months ago

Aptevo Participating in the BIO International Convention

May 22, 2025, 8:05 AM EDT - 3 months ago

Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan

May 15, 2025, 8:05 AM EDT - 4 months ago

Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig

May 8, 2025, 8:45 AM EDT - 4 months ago

Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation

Apr 22, 2025, 4:05 PM EDT - 4 months ago

Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 21, 2025, 2:40 PM EDT - 5 months ago

Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Apr 4, 2025, 4:05 PM EDT - 5 months ago

Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Apr 3, 2025, 8:50 AM EDT - 5 months ago

Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Mar 20, 2025, 8:35 AM EDT - 6 months ago

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

Mar 18, 2025, 8:05 AM EDT - 6 months ago

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

Mar 6, 2025, 8:00 AM EST - 6 months ago

Aptevo to Participate in March Conferences

Feb 15, 2025, 6:59 PM EST - 7 months ago

Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Feb 14, 2025, 8:05 AM EST - 7 months ago

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

Jan 15, 2025, 8:00 AM EST - 8 months ago

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

Dec 12, 2024, 12:50 PM EST - 9 months ago

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

Dec 12, 2024, 9:00 AM EST - 9 months ago

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

Dec 4, 2024, 8:35 AM EST - 9 months ago

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

Nov 29, 2024, 9:55 AM EST - 10 months ago

Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan

Nov 26, 2024, 8:35 AM EST - 10 months ago

Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

Nov 22, 2024, 8:35 AM EST - 10 months ago

Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

Nov 20, 2024, 8:35 AM EST - 10 months ago

First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

Nov 11, 2024, 8:15 AM EST - 10 months ago

First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial

Nov 7, 2024, 8:05 AM EST - 10 months ago

Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update

Sep 18, 2024, 4:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Sep 16, 2024, 8:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules

Aug 13, 2024, 8:05 AM EDT - 1 year ago

Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Aug 8, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update

Jul 1, 2024, 4:20 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $2.75 Million Offering

Jun 28, 2024, 9:20 AM EDT - 1 year ago

Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules

May 14, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA

May 8, 2024, 8:05 AM EDT - 1 year ago

Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update

Apr 15, 2024, 4:05 PM EDT - 1 year ago

Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering

Apr 11, 2024, 8:00 AM EDT - 1 year ago

Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering

Apr 10, 2024, 9:00 AM EDT - 1 year ago

Aptevo Therapeutics Provides Pipeline Update

Mar 18, 2024, 6:00 AM EDT - 1 year ago

Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference

Mar 5, 2024, 8:05 AM EST - 1 year ago

Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update

Mar 4, 2024, 9:00 AM EST - 1 year ago

Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan

Nov 14, 2023, 8:05 AM EST - 1 year ago

Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update

Nov 1, 2023, 7:45 AM EDT - 2 years ago

Aptevo to Present at Bio-Europe Conference

Aug 10, 2023, 8:05 AM EDT - 2 years ago

Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update

DonZulu Sep. 8 at 5:07 PM

$APVO starting a move into january PT 30$ This is hitting bottom

0 · Reply

macstock Sep. 7 at 2:48 AM

$APVO looks like this turd is finally out of suckers to keep it floating

0 · Reply

jerrik Sep. 5 at 3:04 PM

$APVO Not sure which platforms show the press releases so just sharing this video: https://www.redchip.com/media/3243/aptevo-therapeutics-inside-a-top-tier-oncology-pipeline-with-coo-jeff-lamothe

1 · Reply

HFH_Inc Sep. 4 at 3:01 PM

$APVO Wen next Reverse Split?

1 · Reply

Annet_why_net Sep. 4 at 2:54 PM

$APVO 👀

0 · Reply

MrTicker Sep. 4 at 12:51 PM

$APVO Aptevo Expands Anti-Cancer Pipeline With Patents For APVO452, APVO451; Acute Myeloid Leukemia Candidate Mipletamig Shows Strong Clinical Validation BENZINGA 7:50 AM ET 9/4/2025

0 · Reply

The_Gambl3r Sep. 4 at 3:43 AM

$APVO 👀👀

0 · Reply

doodledo77 Aug. 28 at 4:30 PM

$APVO watching... Some just added 56k👀👀

0 · Reply

DaBullRunner Aug. 28 at 11:03 AM

$APVO there it goes PZG loading 🚢📦📦📦📦📦📦📦🚨 WATCH AND LEARN LIKE THIS👇

0 · Reply

doodledo77 Aug. 27 at 8:01 PM

$APVO watching this money maker 👀👀👀😉

1 · Reply

jerrik Aug. 26 at 6:29 PM

$APVO This is getting laughable when this stock is most likely going to be over $10 in the next couple of months. People are trying to save pennies but hopefully this is our double bottom here. Silly.

3 · Reply

David_M_ Aug. 25 at 10:22 PM

$APVO I've seen a lot of posts like this where a bot writes a summary of a stock on a page and that's their only post ever.

1 · Reply

ShadowScholar Aug. 23 at 5:50 AM

$APVO Aptevo Therapeutics is a immuno-oncology company with early stage bispecific antibody platform

0 · Reply

DonZulu Aug. 22 at 3:23 AM

$APVO

0 · Reply

theBigDollarski Aug. 21 at 6:23 PM

$APVO Marvin looking for more saps for his next PIPE.....

0 · Reply

David_M_ Aug. 21 at 6:12 PM

$APVO On its way up!

2 · Reply

macstock Aug. 20 at 2:43 AM

$APVO back under $2 another R/S on the way and more dilution.

0 · Reply

DonZulu Aug. 18 at 6:28 PM

$APVO $UNH moving up will take the health and bio markets with it . Its well deserved been a bad couple years

0 · Reply

jerrik Aug. 14 at 7:35 PM

$APVO So interesting to me how these things wait until a specific low and then they move up so strongly. I saw 1.74 when this first did an R/S and ignored it but that's where it went to and now it's happy to move up. Algos probably.

0 · Reply

BLOCKS77 Aug. 14 at 7:17 PM

$APVO

0 · Reply

waeng Aug. 14 at 7:12 PM

$APVO

0 · Reply

DonZulu Aug. 14 at 4:24 PM

$APVO wait till Rate cuts the whole BIO sector in america has been fckin wrecked by bidens america and short algos

0 · Reply

Market Cap	5.29M
Revenue (ttm)	0.00
Net Income (ttm)	-24.13M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	258,200
Avg Vol	162,880
Day's Range	N/A - N/A
Shares Out	3.29M
Stochastic %K	0%
Beta	5.77
Analysts	Strong Buy
Price Target	$420.00